Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Want to see NRIX full AI Analyst Report?
Total Valuation
Nurix Therapeutics has a market cap or net worth of $1.75B. The enterprise value is $1.50B.
Market Cap$1.75B
Enterprise Value$1.50B
Share Statistics
Nurix Therapeutics has 103,405,815 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding103,405,815
Owned by Insiders0.19%
Owned by Institutions0.39%
Financial Efficiency
Nurix Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -47.26%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-47.26%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee293.64K
Profits Per Employee-924.67K
Employee Count286
Asset Turnover0.12
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nurix Therapeutics is ―. Nurix Therapeutics’s PEG ratio is -0.94.
PE Ratio―
PS Ratio17.45
PB Ratio2.72
Price to Fair Value2.72
Price to FCF-5.56
Price to Operating Cash Flow-7.40
PEG Ratio-0.94
Income Statement
In the last 12 months, Nurix Therapeutics had revenue of 83.98M and earned -264.46M in profits. Earnings per share was -3.05.
Revenue83.98M
Gross Profit65.12M
Operating Income-285.67M
Pretax Income-263.70M
Net Income-264.46M
EBITDA-244.84M
Earnings Per Share (EPS)-3.05
Cash Flow
In the last 12 months, operating cash flow was -260.29M and capital expenditures -11.56M, giving a free cash flow of -271.85M billion.
Operating Cash Flow-260.29M
Free Cash Flow-271.85M
Free Cash Flow per Share-2.63
Dividends & Yields
Nurix Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.51
52-Week Price Change65.97%
50-Day Moving Average15.72
200-Day Moving Average13.89
Relative Strength Index (RSI)64.22
Average Volume (3m)1.30M
Important Dates
Nurix Therapeutics upcoming earnings date is Jul 9, 2026, After Close (Confirmed).
Last Earnings DateApr 8, 2026
Next Earnings DateJul 9, 2026
Ex-Dividend Date―
Financial Position
Nurix Therapeutics as a current ratio of 7.02, with Debt / Equity ratio of 12.20%
Current Ratio7.02
Quick Ratio7.02
Debt to Market Cap0.00
Net Debt to EBITDA0.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nurix Therapeutics has paid 760.00K in taxes.
Income Tax760.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Nurix Therapeutics EV to EBITDA ratio is -5.20, with an EV/FCF ratio of -4.84.
EV to Sales15.17
EV to EBITDA-5.20
EV to Free Cash Flow-4.84
EV to Operating Cash Flow-5.11
Balance Sheet
Nurix Therapeutics has $540.73M in cash and marketable securities with $58.66M in debt, giving a net cash position of $482.08M billion.
Cash & Marketable Securities$540.73M
Total Debt$58.66M
Net Cash$482.08M
Net Cash Per Share$4.66
Tangible Book Value Per Share$6.22
Margins
Gross margin is -139.43%, with operating margin of -340.16%, and net profit margin of -314.90%.
Gross Margin-139.43%
Operating Margin-340.16%
Pretax Margin-314.00%
Net Profit Margin-314.90%
EBITDA Margin-291.55%
EBIT Margin-314.00%
Analyst Forecast
The average price target for Nurix Therapeutics is $30.82, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.82
Price Target Upside76.01% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast48.32%
EPS Growth Forecast-1.91%